GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Shiller PE Ratio

GlycoNex (ROCO:4168) Shiller PE Ratio : (As of Jun. 19, 2024)


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoNex Shiller PE Ratio Historical Data

The historical data trend for GlycoNex's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Shiller PE Ratio Chart

GlycoNex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlycoNex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlycoNex's Shiller PE Ratio

For the Biotechnology subindustry, GlycoNex's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GlycoNex's Shiller PE Ratio falls into.



GlycoNex Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

GlycoNex's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, GlycoNex's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.67/131.7762*131.7762
=-0.670

Current CPI (Mar. 2024) = 131.7762.

GlycoNex Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.169 100.560 -0.221
201409 -0.129 100.428 -0.169
201412 -0.089 99.070 -0.118
201503 -0.219 99.621 -0.290
201506 -0.209 100.684 -0.274
201509 -0.268 100.392 -0.352
201512 -0.318 99.792 -0.420
201603 -0.189 100.470 -0.248
201606 -0.348 101.688 -0.451
201609 -0.298 101.861 -0.386
201612 -0.457 101.863 -0.591
201703 -0.387 102.862 -0.496
201706 -0.507 103.349 -0.646
201709 -0.467 104.136 -0.591
201712 -0.536 104.011 -0.679
201803 -0.894 105.290 -1.119
201806 -1.301 106.317 -1.613
201809 -0.676 106.507 -0.836
201812 -1.292 105.998 -1.606
201903 -0.745 107.251 -0.915
201906 -0.974 108.070 -1.188
201909 -0.994 108.329 -1.209
201912 -0.527 108.420 -0.641
202003 -0.576 108.902 -0.697
202006 -0.676 108.767 -0.819
202009 -0.149 109.815 -0.179
202012 -0.447 109.897 -0.536
202103 -0.447 111.754 -0.527
202106 -0.430 114.631 -0.494
202109 -0.420 115.734 -0.478
202112 -0.480 117.630 -0.538
202203 -0.330 121.301 -0.358
202206 -0.570 125.017 -0.601
202209 -0.640 125.227 -0.673
202212 -0.670 125.222 -0.705
202303 -0.550 127.348 -0.569
202306 0.040 128.729 0.041
202309 -0.550 129.860 -0.558
202312 -0.590 129.419 -0.601
202403 -0.670 131.776 -0.670

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoNex  (ROCO:4168) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


GlycoNex Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of GlycoNex's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoNex (ROCO:4168) Business Description

Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines